Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study

PURPOSE: This Phase I, multicenter, randomized study (ClinicalTrials.gov NCT01220128) evaluated the safety and immunogenicity of recombinant Wilms’ tumor 1 (WT1) protein combined with the immunostimulant AS15 (WT1-immunotherapeutic) as neoadjuvant therapy administered concurrently with standard trea...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Higgins, M., Curigliano, G., Dieras, V., Kuemmel, S., Kunz, G., Fasching, P. A., Campone, M., Bachelot, T., Krivorotko, P., Chan, S., Ferro, A., Schwartzberg, L., Gillet, M., De Sousa Alves, P. M., Wascotte, V., Lehmann, F. F., Goss, P.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2017
Assuntos:
Clinical Trial
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5332485/
https://ncbi.nlm.nih.gov/pubmed/28176175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4130-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados